Oxford Immunotec Global PLC (NASDAQ:OXFD) was the recipient of a large decrease in short interest in December. As of December 31st, there was short interest totalling 411,000 shares, a decrease of 9.6% from the December 15th total of 454,700 shares. Approximately 1.6% of the company’s stock are sold short. Based on an average trading volume of 122,200 shares, the short-interest ratio is presently 3.4 days.

Shares of Oxford Immunotec Global stock traded down $0.24 during midday trading on Tuesday, hitting $16.22. The company had a trading volume of 98,800 shares, compared to its average volume of 88,356. The company has a debt-to-equity ratio of 0.03, a quick ratio of 12.65 and a current ratio of 13.24. The stock has a market capitalization of $437.16 million, a P/E ratio of 31.80 and a beta of 0.48. The company has a 50 day moving average of $16.78 and a 200 day moving average of $15.11. Oxford Immunotec Global has a 52-week low of $12.49 and a 52-week high of $18.60.

Oxford Immunotec Global (NASDAQ:OXFD) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.09. Oxford Immunotec Global had a return on equity of 15.77% and a net margin of 199.21%. The business had revenue of $21.20 million during the quarter, compared to analysts’ expectations of $20.23 million. During the same quarter in the previous year, the business earned ($0.13) earnings per share. The firm’s quarterly revenue was up 31.7% compared to the same quarter last year. Equities research analysts forecast that Oxford Immunotec Global will post -0.1 EPS for the current year.

In other news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $16.45, for a total value of $49,350.00. 4.21% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. First Light Asset Management LLC increased its holdings in shares of Oxford Immunotec Global by 14.5% during the second quarter. First Light Asset Management LLC now owns 3,140,347 shares of the company’s stock valued at $43,211,000 after acquiring an additional 396,868 shares in the last quarter. Millennium Management LLC grew its position in Oxford Immunotec Global by 17.7% during the 3rd quarter. Millennium Management LLC now owns 1,315,387 shares of the company’s stock valued at $21,874,000 after purchasing an additional 197,364 shares during the last quarter. Endurant Capital Management LP grew its position in Oxford Immunotec Global by 57.2% during the 3rd quarter. Endurant Capital Management LP now owns 989,436 shares of the company’s stock valued at $16,454,000 after purchasing an additional 360,200 shares during the last quarter. Granahan Investment Management Inc. MA increased its stake in Oxford Immunotec Global by 4.4% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 812,227 shares of the company’s stock valued at $13,507,000 after purchasing an additional 34,263 shares in the last quarter. Finally, Man Group plc bought a new stake in Oxford Immunotec Global during the 3rd quarter valued at about $12,218,000. 93.48% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have recently weighed in on OXFD. Zacks Investment Research downgraded shares of Oxford Immunotec Global from a “buy” rating to a “hold” rating in a research report on Wednesday, January 8th. ValuEngine upgraded shares of Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research note on Wednesday, September 25th. TheStreet raised shares of Oxford Immunotec Global from a “d+” rating to a “c-” rating in a research report on Tuesday, November 19th. Piper Jaffray Companies set a $20.00 price objective on shares of Oxford Immunotec Global and gave the stock a “buy” rating in a research note on Wednesday, September 18th. Finally, BidaskClub cut shares of Oxford Immunotec Global from a “hold” rating to a “sell” rating in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $19.67.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Read More: What is the outlook for the FAANG stocks?

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.